Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399239 | 1.00 | EGFR (0.44) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL30591163 | 1.00 | EGFR (0.44) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL16585438 | 0.85 | AAK1 (0.48) | AAK1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL25395841 | 0.76 | HTR1A (0.49) | EGFRHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL25395839 | 0.76 | HTR1A (0.49) | EGFRHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL16585441 | 0.72 | SYK (0.47) | AAK1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL28216759 | 0.72 | HTR1A (0.50) | EGFRHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL30480750 | 0.71 | SREBF2 (0.40) | AAK1 | |
| SCHEMBL29053455 | 0.71 | SREBF2 (0.40) | AAK1 | |
| SCHEMBL644819 | 0.71 | CCNE2 (0.44) | AAK1KDM4ECCNE2CCNA2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | EGFR 944/4885PIK3CD 2096/4885ABL1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.